IE51070B1 - Pharmaceutical formulations comprising cisplatatin solutions - Google Patents

Pharmaceutical formulations comprising cisplatatin solutions

Info

Publication number
IE51070B1
IE51070B1 IE715/81A IE71581A IE51070B1 IE 51070 B1 IE51070 B1 IE 51070B1 IE 715/81 A IE715/81 A IE 715/81A IE 71581 A IE71581 A IE 71581A IE 51070 B1 IE51070 B1 IE 51070B1
Authority
IE
Ireland
Prior art keywords
cisplatin
solution
polyethylene glycol
solutions
molecular weight
Prior art date
Application number
IE715/81A
Other languages
English (en)
Other versions
IE810715L (en
Original Assignee
Bristol Myers Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Co filed Critical Bristol Myers Co
Publication of IE810715L publication Critical patent/IE810715L/xx
Publication of IE51070B1 publication Critical patent/IE51070B1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
IE715/81A 1980-03-31 1981-03-30 Pharmaceutical formulations comprising cisplatatin solutions IE51070B1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US13537380A 1980-03-31 1980-03-31

Publications (2)

Publication Number Publication Date
IE810715L IE810715L (en) 1981-09-30
IE51070B1 true IE51070B1 (en) 1986-09-17

Family

ID=22467813

Family Applications (1)

Application Number Title Priority Date Filing Date
IE715/81A IE51070B1 (en) 1980-03-31 1981-03-30 Pharmaceutical formulations comprising cisplatatin solutions

Country Status (30)

Country Link
JP (1) JPS56152415A (cs)
KR (1) KR860000841B1 (cs)
AR (1) AR225500A1 (cs)
AT (1) AT370996B (cs)
AU (1) AU541056B2 (cs)
BE (1) BE888209A (cs)
CA (1) CA1162479A (cs)
CH (1) CH647481A5 (cs)
CS (1) CS246051B2 (cs)
DD (1) DD157762A5 (cs)
DE (1) DE3112272A1 (cs)
DK (1) DK158564C (cs)
ES (1) ES500869A0 (cs)
FI (1) FI70670C (cs)
FR (1) FR2480605A1 (cs)
GB (1) GB2074028B (cs)
GR (1) GR72769B (cs)
HU (1) HU183379B (cs)
IE (1) IE51070B1 (cs)
IL (1) IL62517A (cs)
IT (1) IT1170838B (cs)
LU (1) LU83270A1 (cs)
NL (1) NL8101531A (cs)
NO (1) NO156675C (cs)
NZ (1) NZ196519A (cs)
PH (1) PH17152A (cs)
PT (1) PT72774B (cs)
SE (1) SE455045B (cs)
SU (1) SU1056893A3 (cs)
ZA (1) ZA812084B (cs)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1153974B (it) * 1982-09-23 1987-01-21 Erba Farmitalia Composizioni farmacologiche a base di cisplatino e metodo per il loro ottenimento
NL8303657A (nl) * 1983-10-24 1985-05-17 Pharmachemie Bv Voor injectie geschikte, stabiele, waterige, zoutzuur bevattende oplossing van cisplatine, alsmede werkwijze ter bereiding daarvan.
FI895340A7 (fi) * 1988-11-14 1990-05-15 Bristol Myers Squibb Co Hypertoninen cisplatin-liuos
EP0929293B1 (en) * 1996-08-23 2003-10-22 Sequus Pharmaceuticals, Inc. Liposomes containing a cisplatin compound
AUPQ641100A0 (en) 2000-03-23 2000-04-15 Australia Nuclear Science & Technology Organisation Methods of synthesis and use of radiolabelled platinum chemotherapeutic ag ents
JP4445304B2 (ja) 2004-03-26 2010-04-07 オンキヨー株式会社 スイッチングアンプ
US8852566B2 (en) * 2009-03-26 2014-10-07 Warsaw Orthopedic, Inc. Compositions and methods for preferential distribution of active agents to injury sites
KR102832060B1 (ko) 2018-03-29 2025-07-10 프로젝트 파마슈틱스 게엠베하 액체 약학적 제형

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4177263A (en) * 1972-02-28 1979-12-04 Research Corporation Anti-animal tumor method
SE445172B (sv) * 1978-05-30 1986-06-09 Bristol Myers Co Stabil, steril vattenlosning av cisplatin i enhetsdoseringsform

Also Published As

Publication number Publication date
ES8206545A1 (es) 1982-08-16
SU1056893A3 (ru) 1983-11-23
FI70670B (fi) 1986-06-26
SE455045B (sv) 1988-06-20
FI70670C (fi) 1986-10-06
ATA150481A (de) 1982-10-15
IE810715L (en) 1981-09-30
DE3112272A1 (de) 1982-04-29
JPS56152415A (en) 1981-11-26
HU183379B (en) 1984-04-28
KR860000841B1 (ko) 1986-07-09
ZA812084B (en) 1982-04-28
AT370996B (de) 1983-05-25
IT8148090A0 (it) 1981-03-24
NO156675B (no) 1987-07-27
ES500869A0 (es) 1982-08-16
FR2480605B1 (cs) 1984-05-11
DK144281A (da) 1981-10-01
AU6816681A (en) 1981-10-08
NO156675C (no) 1987-11-04
DE3112272C2 (cs) 1990-09-27
BE888209A (fr) 1981-09-30
DK158564C (da) 1990-11-05
SE8101990L (sv) 1981-11-13
GB2074028A (en) 1981-10-28
GR72769B (cs) 1983-12-02
AU541056B2 (en) 1984-12-13
CS246051B2 (en) 1986-10-16
IL62517A (en) 1984-01-31
DD157762A5 (de) 1982-12-08
JPS6360008B2 (cs) 1988-11-22
DK158564B (da) 1990-06-11
PT72774A (en) 1981-04-01
CH647481A5 (fr) 1985-01-31
FI810934L (fi) 1981-10-01
AR225500A1 (es) 1982-03-31
GB2074028B (en) 1983-09-21
PH17152A (en) 1984-06-13
NO811081L (no) 1981-10-01
IT8148090A1 (it) 1982-09-24
IT1170838B (it) 1987-06-03
KR830004849A (ko) 1983-07-20
CA1162479A (en) 1984-02-21
LU83270A1 (fr) 1981-10-29
FR2480605A1 (fr) 1981-10-23
IL62517A0 (en) 1981-05-20
PT72774B (en) 1982-11-16
NZ196519A (en) 1983-06-17
NL8101531A (nl) 1981-10-16

Similar Documents

Publication Publication Date Title
US4451447A (en) Pharmaceutical formulations
US4322391A (en) Process for the preparation of microcrystalline cisplatin
US4310515A (en) Pharmaceutical compositions of cisplatin
FI78236C (fi) Foerfarande foer framstaellning av en frystorkad doseringsenhet av cis-platina (ii) diamindiklorid.
KR100351713B1 (ko) 백금(ii) 항종양제의 안정용액
Faggiani et al. Heavy transition metal complexes of biologically important molecules. 4. Crystal and molecular structure of pentahydrodioxonium chloro (uracilato-N (1))(ethylenediamine) platinum (II) chloride,(H5O2)[PtCl (NH2CH2CH2NH2)(C4H5N2O2)] Cl, and chloro (thyminato-N (1))(ethylenediamine) platinum (II), PtCl (NH2CH2CH2NH2)(C5H5N2O2)
IE51070B1 (en) Pharmaceutical formulations comprising cisplatatin solutions
NZ189556A (en) Stabilised aqueous solutions of cisplatin
US4946689A (en) Concentrated, stabilized cis-diamminedinitratoplatinum solutions for conversion to cisplatin
Shamsuddin et al. Synthesis and Crystal Structure of a New Antitumor Agent:[Pt (cis-1, 4-Diaminocyclohexane)(1, 1-Cyclobutanedicarboxylate)]
AU623632B2 (en) A solution of carboplatin
RU2157813C2 (ru) Средство, обладающее лейкопоэзстимулирующим, иммуномодулирующим и антибактериальным действием
FI72302B (fi) Foerfarande foer framstaellning av stabilt mikrokristallint ciplatin
Akaboshi et al. Relationship between Cell‐killing Efficiency and Number of Platinum Atoms Binding to DNA, RNA, and Protein Molecules in HeLa Cells Treated with cis‐Diamine (glycolato) platinum (II)
Sergeev et al. The antioxidant properties of histamine receptor blockers: a comparative study in a model system
IE51468B1 (en) Microcrystalline cisplatin and formulations containing it
Głowiak et al. Structure of tetraaqua-bis [μ-(glycylglycinato)-NOO']-dicopper (II) bis (diphenyl phosphate) dihydrate
Cinčić et al. Hydrogen bonding in the bromide salts of 4-aminobenzoic acid and 4-aminoacetophenone
Fa et al. SYNTHESIS AND CHARACTERIZATION IN VITRO ANTIMICROBIAL AND CYTOTOXICITY TESTING OF OXALIC ACID-DERIVED CADMIUM CHELATING AGENTS
Thabet et al. Sodium 1, 6-hexanediammonium cyclotriphosphate dihydrate
Cheng Platinum complexes for the analysis of cis-dichlorodiammine platinum (II)
Montalvo Stability of doxorubicin, dacarbazine, and 5-fluorouracil in plastic syringes
Sharp Developments in the Coordination Chemistry of Arsenium Cations

Legal Events

Date Code Title Description
MM4A Patent lapsed